Syndax Pharmaceuticals, Inc. has announced a significant leadership change as Chief Financial Officer Keith A. Goldan prepares to retire. His departure, effective November 9, 2026, marks a pivotal moment for the company as it transitions to new financial leadership.

Goldan, who has served as the CFO, principal accounting and financial officer, and treasurer, will assist in the transition of his responsibilities before officially retiring. He will remain with the company as an advisor for a short period following his retirement. The company expressed its gratitude for Goldan's dedicated service during his tenure.

Taking over the role of CFO will be Aaron A. Ondrey, who joins Syndax on the same day as Goldan's retirement. Ondrey's appointment is expected to bring fresh perspectives to the company's financial strategies as it navigates the competitive landscape of pharmaceutical preparations.

This leadership change comes at a time when Syndax is looking to strengthen its operational framework and enhance investor confidence. The company recently issued a press release detailing its financial results for the quarter ending September 30, 2026, indicating a proactive approach to transparency and communication with stakeholders.

The transition in leadership is crucial for Syndax as it continues to operate within the pharmaceutical preparations industry, which is characterized by rapid innovation and intense competition. The company is positioned on the Nasdaq under the ticker symbol SNDX.

As part of the filing, Syndax also included its financial results and a presentation, which are available as exhibits to the current report. This comprehensive approach indicates the company's commitment to maintaining a clear line of communication with its investors and the market.

Looking ahead, the filing does not specify any immediate next steps following the leadership transition, but it underscores the importance of a smooth handover to ensure continued operational stability.